Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice. by Sheldon, P. W. & Hill, S. A.
Br. J. Cancer (1977) 35, 795.
HYPOXIC CELL RADIOSENSITIZERS AND LOCAL
CONTROL BY X-RAY OF A TRANSPLANTED TUMOUR
IN MICE
P. AW. SHELDON AND S. A. HILL
From?t the Gdray Laboratory of the Cancer Research Campaign, Mount Vernon Hospital,
Vorthwood, Middx. HA6 2RN
Received 3 December 1976 Accepted 18 January 1977
Summary.-Tumour experiments including local control after X-irradiation have
been performed, using a new technique that eliminates the need for anaesthetics in
restraining the animals. This system has been used to investigate the degree of
sensitization that can be achieved with ICRF 159 and 4 strongly electron-affinic
radiosensitizers, nifurpipone dihydrochloride, metronidazole, Ro-11-3696 and
Ro-07-0582.
No significant enhancement of the radiation effect was observed with ICRF 159.
Significant sensitization was achieved by all 4 nitro-heterocyclic compounds, Ro-07-
0582 being the most effective, metronidazole and Ro-11-3696 the next, and nifur-
pipone dihydrochloride the least effective.
For Ro-07-0582 and metronidazole, several drug concentrations were investigated,
and the interval between injection with Ro-07-0582 and irradiation was varied: an
interval of 30 min gave more sensitization than an interval of 90 min.
The results from the local control experiments using Ro-07-0582 have been com-
pared with those obtained from regrowth delay experiments. The radiosensitization
obtained by the Ro-07-0582 increased with the X-ray dose above 25 gray.
Both metronidazole and Ro-07-0582 gave significant enhancement of effect at
serum concentrations which can be achieved in man.
OXYGEN is metabolized as it diffuses
through the cells surrounding a capillary
blood bessel, thus producing an 02
gradient such that little or none remains
at about 150/am from the capillary (Thom-
linson and Gray, 1955). The resultant
hypoxic cells, which have been demon-
strated in animal tumours (e.g. Thomlin-
son, 1960; Hewitt, Chan and Blake, 1967),
are thought be a reason why X-ray
treatment may sometimes fail in the local
control of tumours (Fowler, 1972).
One method ofovercoming the problem
of hypoxic cell radioresistance is by the
use of chemicals which may act, either by
normalizing " the developing tumour
blood vasculature (Hellmann and Murkin,
1974), or are electron-affinic compounds
which mimic the radiosensitizing effect of
02, but which are not rapidlv metabolized
and so can diffuse further and radio-
sensitize the hypoxic' cells (Adams, 1973).
The present work is concerned with the
use of such chemicals to overcome hypoxic
cell radioresistance, using the local control
(i.e. cure) of tumours in mice irradiated
without anaesthetic as the test system.
Five compounds have been investi-
gated: ICRF 159 which has previously
been reported to " normalise " blood
capillaries within tumours and so promote
an improved 02 supply (Hellmann and
Murkin, 1974), and 4 electron-affinic
hypoxic cell radiosensitizers nifurpipone
dihydrochloride, metronidazole, Ro-11-
3696 and Ro-07-0582, which have all
shown radiosensitization in vitro (Asquith
et al., 1974a, 1974b; Chapman, Reuvers
and Borsa, 1973; Adams, Asquith and
'Watts, 1974; Adams et al., 1976).P. W. SHELDON AND S. A. HILL
MATERIALS AND METHODS
Mice and tumour.-The tumour studied,
the anaplastic MT tumour, arose sponta-
neously in a WHT/Ht mouse in 1964 in
Dr Hewitt's colony at the Gray Laboratory,
and has been maintained since in the same
inbred strain of mice. Its volume-doubling
time was about 1 day at the size used.
The tumour was aseptically cut into
fragments ofless than 1 mm, and by means of
a fine trocar was implanted s.c. over the
sacral region of the back. The mice were
anaesthetized with 60 mg/kg pentobarbitone
sodium during implantation. Tumoursreach-
ing a meandiameter of5-5 i 0 5 mm between
7 and 21 days after implant were selected for
treatment, whilst slower or faster growing
tumours were rejected.
Irradiations.-The mice were irradiated
without anaesthetic. This was achieved by
designing individual mouse boxes consisting
of a lead tube with a perspex window and air
vent at the head end and a lockable perspex
door at the tail end (Fig. 1). The window was
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FIG. 1. Plan of the irradiation set-up. A
tumour isshownexposed to the X-ray beam
emerging from a portal. The change in the
area cut out between the Mark I and Mark
II jigs is shown.
inset so that the lead tube extended beyond
the heads of the mice in order to reduce the
stress produced by visual stimuli. A portion
of the lead tube was cut out to expose the
posterior dorsum bearing the tumour to a
horizontal i.e. laterally directed X-ray beam
(250 kV; 15 mA; 1/4 mm Cu + I mm Al
filter; HVL 1-3 mm Cu; 4-3 gray/min). The
size of the cutout was reduced after early
experiments had demonstrated an 18%
mortality due to intestinal radiation injury.
To ensure that the tumour was still fully
exposed to the X-ray beam, a cardboard
wedge was placed under the hind feet. The
intestinal mortality was in this way reduced
to less than 1%. The mice were left un-
disturbed in the jigs for about 30 min before
starting the irradiation.
Six mice were mounted as 3 pairs in front
of 3 collimated apertures (7 x 2 cm) on a
plate which fitted on the head oftheX-rayset
(Fig. 1). The X-ray doses at the 3 paired
positions were within 0-5% of each other as
checked by a Baldwin-Farmer dosimeter.
To ensure uniform doses throughout the
tumour volume, the mice were turnedthrough
180° halfway through each irradiation.
Hypoxta.-This was produced using D-
shaped metal clamps similar to those de-
scribed by Denekamp and Harris (1975).
Ten minutes before starting the irradiations
the clamps were applied across the base ofthe
tumour, thus occluding the blood supply.
TCD50 determinations.-The single dose of
X-rays required to achieve local control of
50% of the tumours (i.e. TCD50) was deter-
mined by treating groups ofabout 12-18 mice
with a range of X-ray doses. The resulting
response curve, TCD50 value, and standard
error of the mean were computed using the
logit method of calculating the maximum
likelihood. The programme was revised from
that described by Suit, Shalek and Wette
(1965), with the help of Mrs Irene Lansley.
Drugs.-The effect of 5 radiosensitizing
drugs on the TCD50, and on the incidence of
pulmonary metastases observed post mortem
was investigated. The LD50 of each drug
was also determined in miceofthesamestrain,
age, and sex.
(1) ICRF 159: (Razoxane); [1, 2-di(3,5-
dioxopiperazin-1-yl)propane]; (Ro-
03-6060); (mol. wt. 260).
(2) Nifurpipone dihydrochloride: [5-
nitro-2-furaldehyde-N-methylpipera-
zinoacethydrazone dihydrochloride];
(Ro-10-7722); (mol. wt. 368).
(3) Metronidazole: (Flagyl); [1-(2-
hydroxyethyl)-2-methyl-5-nitroimi-
dazole]; (mol. wt. 171).
(4) Ro-11-3696: [1-(2-hydroxy-3-meth-
oxypropyl) - 2-methyl -5-nitroimida -
zole]; (mol. wt. 215).
(5) Ro-07-0582 [1-(2-hydroxy-3-meth-
oxypropyl)-2-nitroimidazole]; (mol.
wt. 201).
Compounds 1, 2, 4 and 5 were kindly
supplied by Roche Products Ltd; Metro-
nidazole was kindly supplied by May &
Baker Ltd.
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Importance of radiation dose on the
effectiveness ofRo-07-0582.-This was investi-
gated by comparing the tumour-control
results (which used curative doses) with those
from a tumour-regrowth delay experiment
(which used non-curative doses), when in
both cases the mice had been injected i.p.
with 1 mg/g Ro-07-0582 30 min before the
irradiation started. In the regrowth experi-
ment, calipers were used to measure 3
mutually perpendicular diameters of the
tumours daily; and delay in reaching a
geometric mean diameter of 10 mm was
determined.
RESULTS
Criteriafor determining local tumour control
Fig. 2 shows the growth ofthe tumours
after single dose of X-rays. The tumours
continued to increase in size for about 3
days after irradiation, and then gradually
shrank. With doses of 60 gray (6000 rad)
or more, the tumours regressed to pre-
irradiation size after about 10 days. For
the tumour to become nonpalpable re-
quired more than 70 gray and this did not
occur until about 21 days. However, the
acute skin reaction which was present at
this time made palpation difficult, and the
earliest accurate assessment to determine
the presence or absence oftumour was not
feasible until 40 days.
Assessments from the first 20 experi-
ments in which mice were kept up to 300
days revealed that, of those tumours
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which had a mean diameter of 1, 2, 3, 4 or
5 mm at any time between 40 and 100
days after irradiation, respectively 0, 30,
60, 90 and 100% subsequently became
definite recurrences. Consequently,
tumours between 2 and 4 mm inclusive
mean diameter (30-90% probability of
later recurrence) were classified as ambi-
guous, and rejected from the analysis.
Those less than 2 mm were classified as
controlled, and those more than 4 mm as
recurrent. Using these criteria, of those
tumours expected to become recurrent,
73%, 92%, 97% and 98% had done so by
40, 60, 80 and 100 days respectively.
Thus 60 days from irradiation was the
shortest time for a relatively accurate
assessment ofthe dose required to achieve
local control of 50% of the tumours.
However, to allow for extended dose
fractionation schedules being used in other
work, we have taken 80 days as the end
time. This has the additional advantage
that only 1% of tumours fell in the
ambiguous classification, compared with
3% at 60 days.
Tumour control data
The TCD50s obtained from 5 separate
control experiments using single doses of
X-rays only were 77-6, 80.0, 77-1, 75-8
and 80-4 gray. The result derived from
combining all these data in a single deter-
mination of the TCD50, which has been
DAYS AFTER IRRADIATION
FIG. 2.-Growth curves of the tumours after single doses of X-rays. By each curve are shown
the X-ray dose (gray) and in brackets, the number ofmice in that dose group. IJpright bars ± s.e.
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used as the control in the present work,
was 79-0 gray. These combined data,
together with that from the other experi-
ments, are shown in Table I.
The TCD50 obtained after irradiating
under fully hypoxic conditions (using the
tumour clamps) was 77-8 gray, 1-2 gray
less than the combined control TCD50
given above. This difference is not signi-
ficant (it is within 1 s.e.), but indicates
that 78-100% of the cells were hypoxic.
Figs 3-6 show the effect of the 5
sensitizing drugs on the control proba-
bilities for tumours in air-breathing mice.
In each figure the combined control line is
shown on the right hand side. The curves
for different drug-treated groups are all
displaced to the left, i.e. showing greater
sensitivity. The degree of radiosensitiza-
tion (i.e. reduction in X-ray dose required
to control 50% of the tumours) observed
for each of the drugs has been sum-
marized in Table II as the Enhancement
Ratio (ER).
Tumour regrowth delay
In an experiment using non-curative
single doses of X-rays, the mean delay in
TABLE I.-Tumour Control Data at 80 DaysforSingle Dose ofX-rays. For aGivenX-ray
Dose, the Number ofTumours Controlled is Shown as a Fraction of the Number Analysed
Condition: Air*
Interval (min): -
Drug (mg/g):
X-ray dose (Gy)
30-0
32-5
35-0
40-0
41-2
44-0
45-0
50-0
55-0
56-0
60-0
62 -0
65-0
65-7
68-0
70-0
75-0
75-9
80-0
85-0
90.0
95 0
TCD50
TCD50 - s.e.
TCD50 + s.e.
No. irradiated
No. analysed
Reason for losses (0):
Metastases
Gut injury
Ambiguous
Others
1/22
4/42
17/44
18/33
25/30
11/11
79-0
78-2
79 9
281
182
Hy- ICRF Nifur- Metro-
poxic 159 pipone nidazole 3696
- 60t 20 30 30 45
- 0-03 0-2 0-1 1-0 0-3
0582
30 30 30
0-1 0-2 0-3
0/11
_ _- 0/15
0/11 0/8 1/11
-- 0/12
- - - 2/11 0/12
1/11 0/10 5/8 -
- - - 1/12
0/13 3/13 2/11 10/10 -
- - - 6/11
0/13 9/14 4/16 16/17 -
11/12
2/3 11/13 11/16 13/13 -
4/12 4/10 7/9 9/10 9/9 -
8/13 9/11 -
75a-0
73-6
76-5
88
50
0
35:
0
8
64-0
62-5
65-4
77
60
91:
1
10
67-5
66-3
68- 7
70
63
0
1§
0
9
53-5
52-3
54-8
87
69
6
3+
2
9
61- 7
60-8
62-8
60
59
0
0§
C)
13/15
16/16
10/10
77-8
76-6
79-1
78
66
5 5
161:§ 4:
4 3
11 4
* Combined dated from 5 experiments.
t See text.
t Mark I jig see text.
§ Mark II jig see text.
0/15
4/10
3/6
7/8
53-4
52-0
54-9
81
50
11
21:
1
5
3/16
10/15
10/14
10/10
49 3
48-3
50-4
70
63
3
1§
1
4
12/23
17/20
18/20
1 7/9
6/6
6/6
45-6
44-6
46-6
187
121
5
23:
2
5
30 90
1-0 0-2
0/12 -
0/15
8/18 -
11/16
- 0/11
13/16 1/17
3/3 7/18
4/18
- 7/10
38-0
37-0
38-9
89
80
0
8:
0
2
57-4
55-1
59-7
78
74
1
0§
4
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FIG. 3.-Radiosensitization of the anaplastic
MT tumour at 80 days by either ICRF
159 (0) ornifurpipone dihydrochloride (A)
compared with those receiving X-rays only
(x). The TCD50s ± s.e. are shown.
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FIG. 4.-Radiosensitization of the anaplastic
MT tumour at 80 days by the 5-nitro-
imidazole compounds, metronidazole and
Ro-11-3696. The TCD50s ± s.e. are
shown.
the times that each individual tumour
took to regrow to a mean diameter of
10 mm was determined as a function of
X-ray dose. The mean delay was then
calculated for each treatment group.
Fig. 7 shows the dose reponse curves
obtained with or without Ro-07-0582
(1 mg/g). The degree of radiosensitization
achieved, expressed as the enhancement
ration (ER), was about 1-5 with X-ray
(loses of 2-5 gray or less, but then increased
rapidly to give a maximum ER of about
1-8 for a dose of 3-0 gray.
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FIG. 5. Radiosensitization of the anaplastic
MT tumour at 80 days by the 2-nitro-
imidazole Ro-07-0582 at 1 mg/g (0),
0 3 mg/g (O]), 0-2 mg/g (V) and 0-1 mg/g
(0),comparedwith X-rays alone ( x). The
TCD50s s.e. are shown.
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FIG. 6.-Radiosensitization of the anaplastic
MT tumour at 80 days by 0-2 mg/g Ro-07-
0582 injected i.p. either 30 min (V) or 90
min (A) before starting the irradiation
compared with those receiving X-rays only
(x). The TCD50s + s.e. are shown.
Metastases
Table I shows the incidence of pul-
monary metastases observed post mortem
in all the experimental groups. The
incidences are expressed as a percentage of
the number of mice irradiated in each
group. The incidence in the control
group which received X-rays only was
5% (14/281). The significance of any
difference between the incidence of meta-
stases in the drug-treated mice and this
control value was assessed by the chi-
squared test. Because of the small
799
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TABLE II.-Summary of the Enhancement Achieved with the Five Sensitizers. The LD50
for Each Sensitizer in Female WHT/Ht Mice is Shown in Parentheses in First Column
Compound
ICRF 159 ( 1-2 mg/g)
Nifurpipone (0-4 mg/g)
Metronidazole (3-5 mg/g)
Ro-11-3696 (3-3 mg/g)
Ro-07-0582 (1-8 mg/g)
Dissolved in
0.5% CMC*
0.9% Saline
0-9% Saline
0-9% Saline
0 9% Saline
0 9% Saline
0.9% Saline
0 9% Saline
0.9% Saline
0-9% Saline
Volume (ml)
injected
i.p./24 g
mouse
0-2
0-8
0-8
0-8
0-8
0-8
0-8
0-8
0-8
0-8
Dose
given
(mg/g)
0 03
0-2
0-1
1.0
0 33
0-1
0-2
0-2
0-3
1-0
Interval
(min)
60t
20
30
30
45
30
30
30
30
30
ER (±s.e.)
1-05 (1.02-1 09)
1-23 (1-201-28)
1-17 (1-14-1-21)
1-48 (1-43-1-53)
1-28 (1-25-1-32)
1- 48 (1-42-1-54)
1-60 (1-55-1-65)
1-38 (1-31-1-45)
1- 73 (1- 68-1-79)
2-08 (2-01-2-16)
* Carboxymethylcellulose in 0.9% saline.
t Injected daily from implant till day ofirradiation. Interval from final injection to start of irradiation.
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FiG. 7.-The time taken to regrow to 10 mm
mean diameter as a function of X-ray dose
is shown ( ± s.e.). Radiosensitization by
1-0 mg/g Ro-07-0582 (0) is compared
with those receiving X-rays only (x).
With the exception of the 0 gray +
Ro-07-0582 dose point (S0), all dose
responses were determined concurrently.
The effect of the size of the X-ray dose on
the enhancement ratio is shown.
numbers of animals available for analysis,
the differences are not statistically sig-
nificant.
DISCUSSION
The present work has shown that in
mice kept up to 300 days after treatment,
the vast majority of tumours that are
going to recur have done so by 60 days,
because of the tumours' fast growth rate.
Consequently, if analysed at 80 days
rather than 60 days, the TCD50 only
increased on average by 0-6 gray (i.e.
<1%). Nevertheless, 80 days was taken
as the end point for analysis.
Assuming that factors such as cell loss
and growth fraction remain constant, and
that the volume-doubling rate is not
slower in an irradiated tumour than an
unirradiated tumour, since the tumour has
a volume-doubling time from 5*5 mm (size
at irradiation) to 6-9 mm mean diameter of
1 day (Fig. 2), 80 volume doublings were
theoretically possible in the 80 days. This
is a longer relative delay than we have
used in assessing another tumour-control
system: the C3H mouse mammary
carcinoma (Fowler et al., 1975). With
that tumour, which has a volume-
doubling time from 6-5 mm (size at
irradiation) to 8-2 mm mean diameter
of about 6 days, only 25 volume doublings
were theoretically possible in the 150 days
used.
The MT tumour is very radioresistant
(TCD50 of 79 gray) and appears to be
virtually all hypoxic, as judged from the
lack ofchangewhenthetumourisclamped.
This is in conflict with the hypoxic
fraction of 5% found by McNally who
irradiated the tumour cells in situt, but
excised the tumours immediately after-
wards and assayed the surviving fraction
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in vitro. However, this may be explained
by the different abilities of oxic and
chronically hypoxic cells of the tumour to
recover from potentially lethal damage
(PLD) (McNally and Sheldon, 1977).
The presence of hypoxic cells in the
MT tumour was a requisite in order to
observe sensitization by specific hypoxic
cell radiosensitizing drugs. Four such
electron-affinic radiosensitizers were in-
vestigated, and found to be most effective
in the order Ro-07-0582, metronidazole,
Ro-11-3696 and nifurpipone dihydro-
chloride. The other sensitizer tested,
ICRF 159, was not thought to act in the
same way, and was found to be the least
effective.
The electron-affinic drugs used were all
nitro-heterocyclic, 3 of them being nitro-
imidazoles, and the fourth a nitrofuran.
They have all been shown to be effective
radiosensitizers in vitro, and two of them,
Ro-07-0582 and metronidazole, have al-
ready been shown to be so effective in a
variety of animal tumours that they are
already being tested in phase I and II
clinical trials.
The in vivo toxicity of a potential
radiosensitizer is a major factor in deter-
mining its relative usefulness. Unfortu-
nately, the precise nature of the toxicity
ofthe compounds used in the present work
is poorly documented. However, the
nitroimidazole and nitrofuran compounds
are primarily neurotoxic (Olivarius, 1956;
Scharer, 1972), whereas ICRF 159 pro-
duces bone marrow depression and in-
testinal toxicity (Bakowski, 1976).
The compounds will be discussed in
order oftheir apparent effectiveness in the
MT tumour.
Relative effectiveness of the compounds as
radiosensitisers
The relative effectiveness of the differ-
ent compounds as radiosensitizers depends
upon the degree of sensitization that can
be obtained for an equal level of toxicity.
We have achieved this by plotting the
enhancement ratio (ER) against the con-
centration of drug expressed as a percen-
tage of the LD50 required to achieve that
enhancement (Fig. 8). The most effective
compounds will be towards the top left
hand quadrant.
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FiG. 8.-Comparison of the efficiency of the
5 radiosensitizing drugs. For agiven drug
dose, the enhancement ratio achieved is
plotted against the relative toxicity of that
drug dose (i.e. expressed as a percentage of
the LD50).
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It can be seen that the most promising
compounds are the nitroimidazoles. For
a given level of toxicity, the 2-nitroimi-
dazole, Ro-07-0582, was more effective
than either of the 5-nitroimidazoles,
metronidazole or Ro-11-3696. As Ro-
11-3696 has the same 2-hydroxy-3-meth-
oxypropyl side chain as Ro-07-0582, the
point of substitution of the nitro group,
rather than the nature of the side chain,
would appear to be the major factor
determining the relative effectiveness of a
nitro-imidazole as a radiosensitizer in
vivo.
The nitrofuran, nifurpipone dihydro-
chloride, was not as effective as the nitro-
imidazoles, a high toxicity producing only
a modest level of sensitization.
The least effective compound was
ICRF 159, although neither we nor other
workers have tested this compound sys-
tematically over a range of doses.
Ro-07-0582 is a small uncharged mole-
cule which has an octanol: water partition
coefficient of 0 4 (Adams et at., 1976). It
hasbeen shown to radiosensitize both ano-
xic bacteria and mammalian cells cultured
1-9; I
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in ?vitro, giving maximum ERs of 2'8 and
2-5 respectively (Asquith et al., 1974b). In
the present work, ERs of 1P5 to 2-1 were
obtained after i.p. injections of 01 to
I 0 mg/g of drug (Fig. 5, Table II). These
are similar to those found by other
workers studying tumour radiosensitiza-
tion (Table V). The serum concentrations
30 min after injection of 0 25 and 190 mg/g
of drug (the time interval used in the
present experiments) have been measured
bv polarograph to be 210 and 1000 ,ag/ml
respectively (Foster, unpublished). These
concentrations in culture medium give
ERs of 1-9 and 2-4 (Adams et al., 1976).
The half-life of Ro-07-0582 has been
determined in serum and in gross tumour
samples, both in mouse and in man. The
half-life is onlv 1-1 I h in mouse serum
(Foster, unpublished) whereas it is 10-18 h
in man (Foster et al., 1975). Because of
this shorter half-life in the mouse, the
interval between injection and irradiation
is important. Fig. 6 and Table II show
that the observed sensitization was greater
with a 30-min interval than with a 90-min
interval, for a low drug dose of 0-2 mg/g.
This is compatible with the decline in
serum concentration from 210 ,ug/ml at
30 min to 130pig/ml at 90 min for a
similar dose (0.25 mg/g) (Foster, un-
published).
The clinical tolerance to Ro-07-0582
has also been determined in tests of this
compoound as a tumour radiosensitizer.
Single doses of 140 mg/kg are tolerated
(Grav et al., 1976), yielding serum con-
centrations of 220 ,ug/ml, somewhat higher
than for an equivalent body dose in mice.
This may- also result in a higher tumour
concentratioin, since mouse tumours have
been shown generally to contain < 4000
of the serum level, whereas human
tumours attain about 90%o of the serum
concentration, probably because of the
differences in half-lives (Discheetal., 1977).
Thus, the ER of 1 6 obtained for 0-2 mng/g
ofthis drug is perhaps an underestimate of
the sensitization that would be achieved
for hypoxic cells in human tumours.
However, because all tumour cells are not
hypoxic, the effect of the sensitizer will
be maximalonly withlargeradiation doses.
The regrowth-delay experiments showed
that the ER for 1 mg/g Ro-07-0582 was
only 1P5 for low radiation doses, although
it increased as the radiation dose increased
above 25 gray, to give an ER of 1 8 for
30 gray X-rays (in the tumour-control
experiment, the ER was 2-1 for 38 grav).
Although no " break point " is detect-
able in Fig. 7, the increase of sensitization
as a function of radiation dose supports
the idea that less than 80-100% of the
cells are hypoxic. The absence of a
" break-point, ", and the increase of sensi-
tization as a functionofradiation dose, has
also been observed in another tumour, a
fibrosarcoma (Denekamp and Stewart,
unpublished).
The change in ER with radiation dose
would have obvious clinical implications,
as clinical radiation doses per fraction are
usually relatively small, and reoxygena-
tion may occur between fractions. How-
ever, Thomlinson et al. (1976) have
already demonstrated an ER of at least
1P2 for a single dose of 8 gray, given to
subcutaneous metastases from a human
carcinoma of the cervix.
Metronidazole is a 5-nitroimidazole
compound verv similar to Ro-07-0582.
It is also a small, uncharged molecule, has
anoctanol:waterpartitioncoefficient of1 1,
is slowly metabolized, andhas along serum
half-life (Asquith et al., 1974a). It has
been shown to sensitize anoxic bacteria
and mammalian cells in vitro, giving a
maximum ER in mammalian cells of 1-9
(Foster and Willson, 1973; Chapman et al.,
1973; Asquith et al., 1974a).
In the present work, an ER of 1P5 was
obtained for a dose of 10 mg/g and ain
ER of 1.2 for a 10-fold lower dose (Fig. 4,
Table II). These results agree well with
those from other studies (Table IV). The
doses administered here should correspond
to 100 and 850 p.g/ml serum concentrations
(Deutsch et al., 1975), which in vitro would
yield ERs of 193 and 197 respectivelv,
close to those observed in vivo.
The clinical tolerance formetronidazole
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has been established recently in trials of
this drug as a potential tumour radio-
sensitizer. The maximum tolerated dose
is about 180 mg/kg, which produces a
serum level of 200,ug/ml (Deutsch et al.,
1975). Thus an ER of 1-2 obtained for the
lowest dose tested in the anaplastic MT
tumour is probably a slight underestimate
of what could be achieved clinically, but
nevertheless still corresponds to an
increase in the local control rate of from
20 to 80% (see Fig. 4). Furthermore,
metronidazole has already shown adistinct
benefit in the treatment of patients with
glioblastoma, using an unconventional
fractionation scheme of 9 X 3 gray (Urta-
sun et al., 1976). The average lifespan of
the patients was increased significantly in
the metronidazole-treated group.
Ro-11-3696 has a 5-nitroimidazole ring
structure (like metronidazole) with a
2-hydroxy-3-methoxypropyl side chain
(like Ro-07-0582). In mammalian cells in
vitro it has been found to be a better
radiosensitizer than metronidazole, but
not as good as Ro-07-0582. A maximum
ER of 2-4 was obtained for 2150,ug/ml of
Ro-11-3696 in vitro (Adams et al., 1976).
In the present work, an ER of 1-3 was
obtained with 0 33 mg/g ofdrug. A direct
comparison of this response with that
obtained in vitro is not possible, as no
serum measurements have been made in
mice.
Nifurpipone dihydrochioride, the only
nitrofuran tested, is water-soluble, and
has been shown specifically to radio-
sensitize hypoxic mammalian cells in vitro
by a factor of at least 2-3 (cf OER 2.7)
(Adams et al., 1974). In vivo, the drug
does not appear to be so promising. The
drug is more toxic than the nitroimidazoles
tested, having an LD50 in WHT/Ht mice
of 0 4 mg/g. The maximum ER that has
been observed in vivo is 1-45 for artificially
hypoxic mouse skin (Denekamp, Michael
and Harris, 1974) at a dose of 0.24 mg/g.
At the slightly lower dose used here
(0-2 mg/g) the ER was only 1-2 (Fig. 3,
Table II). Thus the sensitization that can
be achieved in vivo, with doses that are
close to the lethal range, is very much less
thanwouldbeanticipatedfrominvitrodata.
The reason for this is not known. Inacti-
vation by binding with serum proteins
does not seem to be the reason, since
changing the serum concentration in vitro
did not effect cytotoxicity (Adams et al.,
1974). A more likely reason is rapid
metabolism or excretion, properties that
have limited the usefulness of other
nitrofuran compounds (Adams etal., 1974).
ICRF 159 is the only compound tested
that was not selected on the basis of its
electron affinity, although its ketone
groups do make it weakly electron affinic.
It has been reported tohavemanydifferent
actions, including blocking the cell cycle
at the radiosensitive G2/M phase, poten-
tiating the action of radiomimetic alkyl-
atingagents,and 'iormalising' thedevelop-
ing tumour vasculature (so possibly reduc-
ing the tumourhypoxia) (Bakowski, 1976).
The effectiveness of ICRF 159 as a
radiosensitizer in mice is summarized in
Table V. Hellmann and Murkin (1974)
achieved an ER of about 2 when 1-25 mg/
kg was injected 60 min before each of 5
fractions of X-rays. Similarly, Peters
(1976) observed an ER > 1P2 when mice
TABLE V.-Radiosensitization of Mouse Tumour Systems by ICRF 159. In all Cases the
Interval between Final Injection of Drug and Start ofIrradiation was 60 min
Experimental
system
Cure
Cure
Cure
Regrowth delay
Tumour
WHT An MT
C3H mam Ca
WHT Sq Ca G
S 180
Treatment
30 ,ug/g before single dose X-rays*
30 ug/g before single dose X-rayst
30 ,Ag/g before single dose X-rays*
1 *25 ,ug/g before each of 5 fractions
* Drug injected daily from implant to day of irradiation.
t Drug injected for only 5 days prior to irradiation.
ER Author
1 05 Present work
0*99 Sheldon, unpub.
>1*19 Peters, 1976
2 Hellmann & Murkin, 1974
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which had been injected daily, (from
implantation to day of irradiation,) with
30 mg/kg, were given the final injection
60 min before a single X-ray dose.
In the present work, we administered
30 mg/kg ICRF 159 in the same manner as
Peters (1976), but achieved adisappointing
ER of only 1 05. Likewise, with a C3H
mammary tumour (unpublished), using
30 mg/kg injected for 5 days before a
single X-ray dose, with the final injection
60 min before irradiation, we observed Ino
radiosensitization.
In conclusion, the effectiveness of
ICRF 159 as a radiosensitizing agent in
vivo has differed greatly between tumours,
and in the present tumour it is much less
effective than the other compounds tested.
Effect of radiosensitizing drugs in the
development of metastases
The incidence of metastasis is rela-
tively low for this tumour, comprising
only about 500 of the mice treated with
X-rays above. None of the drugs signi-
ficantly increased the incidence of pul-
monary metastasis. In 2 experiments,
using 1 mg/g of Ro-07-0582 and 0 03 mg/g
ICRF 159,no metastaseswereobserved, but
thegroupsofmicewerenotlargeenoughfor
this reduction from 500 to 000 to be signi-
ficant at the 500 level of probability.
Nevertheless, the reduction in metastases
with ICRF 159 is in agreement with
that ofother workers who have shown that
the drug prevents theseeding ofmetastases
(Hellmann and Burrage, 1969; Salisbury,
Burrage and Hellmann, 1970; Peters,
1975). However, in similar TCD50 experi-
ments with the C3H mammary carcinoma,
which has a higher natural incidence of
metastases, we observed no reduction in
the level of metastases (8/30 vs 5/19) in
those mice whose tumours were locally
controlled (Sheldon andHill, unpublished).
Since ICRF 159 must be administered
from the day ofimplantation to achieve its
antimetastatic effect, and these experi-
ments included administration of 0 03
mg/g/day for only 5 days prior to irradia-
tion, whereas implantation had been
performed 2-6 weeks before, it is probable
that the metastases had already seeded
before the treatment with the drug.
However, this particular aspect makes the
drug of limited clinical applicabilitv as an
antimetastatic agent.
CONCLUSIONS
(1) In this rapidly growing tumour,
80 days is long enough to wait
for assessing the local control of
irradiated tumours.
(2) The hypoxic fraction is difficult to
determine. The radioresistant
tumour (TCD50 79 gray) is not
made moreradioresistantbyclamp-
ing. This is compatible with 1000%
of the cells being hypoxic. How-
ever, the differential ability of
chronically hypoxic cells to recover
from potentially lethal damage
makes this also compatible with
500/ of the cells being hypoxic, as
estimatedbyMcNally. The change
in ER with the size of X-ray dose
also suggests that less than 100%
of the cells are hypoxic.
(3) No drug tested significantly in-
creased the observed incidence of
metastasis.
(4) The most effective radiosensitizer
was Ro-07-0582, with metronid-
azole and Ro-11-3696 next, and
then nifurpipone dihydrochloride,
with no significant radiosensitiza-
tion being achieved with ICRF 159.
(5) Ro-07-0582 and metronidazole are
nearly as effective radiosensitizers
in vivo as they are in vitro. Ro-11 -
3696, however, was not as effective
in vivo as would have been pre-
dicted from the in vitro studies,
and nifurpipone dihydrochloride
was very much less effective in vivo
than in vitro.
(6) Ro-11-3696 which is a 5-nitro-
imidazole like metronidazole but
has the same side chains as Ro-07-
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0582, was only as effective a
radiosensitizer in vivo as metronid-
azole.
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